Your browser is no longer supported. Please, upgrade your browser.
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-21.27 Insider Own20.60% Shs Outstand90.90M Perf Week-7.82%
Market Cap29.20B Forward P/E- EPS next Y-14.47 Insider Trans-9.28% Shs Float63.65M Perf Month-4.23%
Income-1575.60M PEG- EPS next Q-4.81 Inst Own62.20% Short Float3.46% Perf Quarter7.20%
Sales265.70M P/S109.88 EPS this Y-13.80% Inst Trans-0.15% Short Ratio5.83 Perf Half Y26.14%
Book/sh42.57 P/B7.20 EPS next Y18.80% ROA-33.40% Target Price314.02 Perf Year86.80%
Cash/sh48.82 P/C6.28 EPS next 5Y24.00% ROE-47.30% 52W Range118.55 - 388.97 Perf YTD18.60%
Dividend- P/FCF- EPS past 5Y-60.30% ROI-37.50% 52W High-21.21% Beta0.87
Dividend %- Quick Ratio4.50 Sales past 5Y103.70% Gross Margin74.60% 52W Low158.51% ATR17.16
Employees5300 Current Ratio4.60 Sales Q/Q75.90% Oper. Margin- RSI (14)36.85 Volatility4.74% 4.29%
OptionableYes Debt/Eq0.13 EPS Q/Q29.50% Profit Margin- Rel Volume0.57 Prev Close319.39
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume377.93K Price306.46
Recom2.20 SMA20-13.40% SMA50-3.87% SMA20019.06% Volume214,112 Change-4.05%
Mar-01-21Downgrade CLSA Outperform → Underperform $330 → $321
Nov-09-20Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20Downgrade Piper Sandler Neutral → Underweight $175 → $185
Nov-06-20Downgrade Maxim Group Buy → Hold
Jul-10-20Downgrade CLSA Buy → Outperform
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
Mar-02-21 07:00AM  
Feb-27-21 01:21AM  
Feb-26-21 07:00AM  
06:41AM  
Feb-25-21 04:05PM  
Feb-17-21 05:00PM  
09:33AM  
07:00AM  
Jan-27-21 05:45PM  
Jan-26-21 10:01PM  
Jan-23-21 01:52AM  
Jan-15-21 09:34AM  
Jan-14-21 04:35PM  
Jan-13-21 11:00PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
07:00AM  
Jan-07-21 07:00AM  
Dec-27-20 11:00PM  
Dec-14-20 09:10PM  
Dec-11-20 06:17PM  
Dec-07-20 07:00PM  
10:00AM  
Dec-06-20 12:30PM  
Dec-01-20 11:00PM  
04:15PM  
Nov-23-20 07:00AM  
Nov-20-20 07:37AM  
Nov-19-20 08:00PM  
Nov-17-20 07:00AM  
Nov-07-20 08:04AM  
Nov-05-20 04:05PM  
09:00AM  
Oct-09-20 07:05AM  
Oct-06-20 07:00AM  
Oct-01-20 12:00PM  
08:15AM  
Sep-27-20 06:12AM  
Sep-21-20 07:00AM  
Sep-17-20 06:05PM  
Sep-10-20 09:00AM  
Sep-09-20 07:00AM  
Sep-04-20 09:15AM  
Aug-27-20 08:02AM  
07:00AM  
Aug-25-20 07:00AM  
Aug-24-20 08:08AM  
Aug-07-20 12:00PM  
Aug-06-20 04:05PM  
Aug-05-20 07:00AM  
Jul-27-20 09:15AM  
Jul-24-20 06:12PM  
Jul-20-20 07:53AM  
06:30AM  
Jul-17-20 09:00AM  
Jul-16-20 10:31AM  
Jul-15-20 05:00PM  
04:19AM  
Jul-14-20 03:43PM  
08:43AM  
Jul-13-20 10:51AM  
10:11AM  
07:53AM  
06:40AM  
02:03AM  
Jul-12-20 09:30PM  
08:00PM  
Jul-10-20 11:11AM  
Jul-05-20 04:04PM  
Jul-02-20 07:00AM  
Jul-01-20 06:00PM  
08:12AM  
07:00AM  
Jun-30-20 07:30PM  
Jun-22-20 09:00AM  
Jun-19-20 12:27AM  
Jun-18-20 07:30AM  
Jun-12-20 02:30AM  
Jun-05-20 07:30AM  
Jun-03-20 07:15AM  
May-29-20 08:00AM  
08:00AM  
May-26-20 04:05PM  
04:04AM  
02:00AM  
May-21-20 07:00AM  
May-20-20 07:00AM  
May-15-20 07:00AM  
May-14-20 05:45PM  
09:00AM  
May-11-20 04:05PM  
Apr-29-20 05:00PM  
Apr-20-20 04:05PM  
Apr-13-20 04:05PM  
Apr-10-20 06:00PM  
Mar-26-20 02:30PM  
Mar-25-20 09:00AM  
Mar-19-20 05:09PM  
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huang JaneCMO, HematologyFeb 26Option Exercise29.491,50044,2351,500Mar 02 04:52 PM
Huang JaneCMO, HematologyFeb 26Sale320.731,500481,0990Mar 02 04:52 PM
Huang JaneCMO, HematologyJan 29Option Exercise29.491,50044,2351,500Feb 02 04:49 PM
Huang JaneCMO, HematologyJan 29Sale322.991,500484,4920Feb 02 04:49 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Option Exercise6.5012,60081,90012,600Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Sale344.9012,6004,345,6890Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Option Exercise6.501,4009,1001,400Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Sale344.471,400482,2560Jan 19 05:04 PM
BAKER BROS. ADVISORS LPDirectorJan 04Sale220.50121,15426,714,457968,943Jan 06 06:32 PM
Huang JaneCMO, HematologyDec 29Option Exercise29.491,50044,2351,500Dec 30 04:34 PM
Huang JaneCMO, HematologyDec 29Sale249.131,500373,6900Dec 30 04:34 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Option Exercise0.871,497,2001,300,0001,573,715Dec 16 04:43 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Sale229.0491,90021,048,4540Dec 16 04:43 PM
BAKER BROS. ADVISORS LPDirectorDec 04Sale220.501,511,546333,295,893979,003Dec 04 05:24 PM
Huang JaneCMO, HematologyNov 30Option Exercise29.491,50044,2351,500Dec 02 05:01 PM
Huang JaneCMO, HematologyNov 30Sale267.821,500401,7230Dec 02 05:01 PM
Huang JaneCMO, HematologyOct 29Option Exercise29.491,50044,2351,500Nov 02 04:44 PM
Huang JaneCMO, HematologyOct 29Sale300.061,500450,0930Nov 02 04:44 PM
Wang XiaodongChair, Scientific Advisory BrdOct 16Sale320.005,0001,600,0000Oct 20 04:44 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Option Exercise6.5014,00091,00014,000Oct 07 04:50 PM
Wang XiaodongChair, Scientific Advisory BrdOct 05Sale300.005,0001,500,0000Oct 07 04:56 PM
Wu XiaobinPresident & GM ChinaOct 05Sale300.004,0001,200,0000Oct 07 04:52 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Sale299.6014,0004,194,4130Oct 07 04:50 PM
Huang JaneCMO, HematologySep 29Option Exercise29.491,50044,2351,500Oct 01 04:52 PM
Huang JaneCMO, HematologySep 29Sale280.381,500420,5680Oct 01 04:52 PM
OYLER JOHNChief Executive OfficerSep 29Sale280.8223,3036,544,0300Sep 30 04:53 PM
OYLER JOHNChief Executive OfficerSep 28Sale280.0731,0008,682,0630Sep 30 04:53 PM
Wang XiaodongChair, Scientific Advisory BrdSep 25Sale280.425,0001,402,1160Sep 29 04:59 PM
Wu XiaobinPresident & GM ChinaSep 25Sale280.354,0001,121,4060Sep 29 04:57 PM
Wang XiaodongChair, Scientific Advisory BrdSep 17Sale260.275,0001,301,3560Sep 21 04:53 PM
Wu XiaobinPresident & GM ChinaSep 17Sale260.334,0001,041,3270Sep 21 04:50 PM
OYLER JOHNChief Executive OfficerSep 16Sale254.7727,2756,948,8070Sep 16 05:12 PM
OYLER JOHNChief Executive OfficerSep 15Sale254.2634,2148,699,3810Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Option Exercise6.5014,00091,00014,000Sep 16 05:10 PM
OYLER JOHNChief Executive OfficerSep 14Sale250.2519,7394,939,7820Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Sale250.2714,0003,503,7640Sep 16 05:10 PM
Huang JaneCMO, HematologySep 03Sale233.073,128729,0450Sep 08 04:44 PM
OYLER JOHNChief Executive OfficerSep 02Sale229.2227,8076,374,0240Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerSep 01Sale233.7920,2744,739,8090Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerAug 31Sale240.8612,9613,121,7650Sep 02 05:44 PM
Huang JaneCMO, HematologyAug 28Option Exercise29.493,00088,4703,000Sep 01 04:41 PM
Huang JaneCMO, HematologyAug 28Sale242.213,000726,6260Sep 01 04:41 PM
OYLER JOHNChief Executive OfficerAug 21Sale240.1940,7889,796,7750Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 20Sale234.6221,5235,049,7490Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 19Sale234.5629,8667,005,2650Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 14Sale211.158,7051,838,0340Aug 14 05:30 PM
OYLER JOHNChief Executive OfficerAug 13Sale214.4814,4433,097,7620Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Option Exercise31.592,89791,5162,897Aug 12 05:02 PM
OYLER JOHNChief Executive OfficerAug 12Sale212.1019,8204,203,7660Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Sale212.002,897614,1650Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Option Exercise31.591,90360,1161,903Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Sale213.041,903405,4090Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Option Exercise31.592,20069,4982,200Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Sale214.042,200470,8860Aug 12 05:02 PM
Wang XiaodongChair, Scientific Advisory BrdAug 10Sale211.064,000844,2290Aug 12 04:38 PM
OYLER JOHNChief Executive OfficerAug 05Sale223.2717,2543,852,2730Aug 05 05:43 PM
OYLER JOHNChief Executive OfficerAug 04Sale220.4315,3833,390,9510Aug 05 05:30 PM
OYLER JOHNChief Executive OfficerAug 03Sale221.7825,1765,583,5750Aug 05 05:30 PM
Huang JaneCMO, HematologyJul 29Option Exercise94.953,000284,8353,000Jul 31 04:24 PM
Huang JaneCMO, HematologyJul 29Sale209.933,000629,7870Jul 31 04:24 PM
OYLER JOHNChief Executive OfficerJul 22Sale238.3427,7486,613,5030Jul 22 06:22 PM
OYLER JOHNChief Executive OfficerJul 21Sale251.8326,4136,651,6950Jul 22 06:14 PM
OYLER JOHNChief Executive OfficerJul 20Sale251.8528,7627,243,7840Jul 22 06:14 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.3112,0003,015,7400Jul 22 04:47 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.985,0001,259,8960Jul 22 04:47 PM
Wu XiaobinPresident & GM ChinaJul 20Sale250.162,600650,4070Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 17Sale245.74700172,0150Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 15Sale241.112,700650,9980Jul 15 05:14 PM
Wu XiaobinPresident & GM ChinaJul 13Sale220.003,000660,0000Jul 15 05:14 PM
OYLER JOHNChief Executive OfficerJul 08Sale201.3917,5293,530,2060Jul 08 05:20 PM
Huang JaneCMO, HematologyJul 07Option Exercise160.403,921628,9283,921Jul 09 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 07Sale200.006,0001,200,0000Jul 09 04:45 PM
Huang JaneCMO, HematologyJul 07Sale200.003,921784,2000Jul 09 04:43 PM
OYLER JOHNChief Executive OfficerJul 07Sale198.8619,0233,782,9870Jul 08 05:20 PM
OYLER JOHNChief Executive OfficerJul 06Sale197.1117,3623,422,2620Jul 08 05:20 PM
OYLER JOHNChief Executive OfficerJul 01Sale191.573,816731,0160Jul 01 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale190.754,847924,5720Jul 06 04:52 PM
Huang JaneCMO, HematologyJun 29Option Exercise29.491,50044,2351,500Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 29Sale192.601,435276,3740Jul 01 04:43 PM
Liang HowardCFO & Chief Strategy OfficerJun 29Sale191.2330057,3680Jul 01 04:38 PM
Huang JaneCMO, HematologyJun 29Sale190.831,935369,2500Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Option Exercise160.402,079333,4722,079Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Sale200.292,079416,3970Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 24Sale187.3414,3812,694,1560Jun 24 08:23 PM
OYLER JOHNChief Executive OfficerJun 23Sale186.8815,0702,816,22214,381Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 23Sale186.386,0001,118,2980Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 22Sale182.4310,2811,875,60529,451Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 22Sale181.335,000906,6730Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 10Sale175.07900157,5630Jun 12 04:14 PM
Liang HowardCFO & Chief Strategy OfficerJun 08Sale170.8445377,3910Jun 10 05:17 PM
Wu XiaobinPresident & GM ChinaJun 08Sale170.832,800478,3170Jun 10 05:15 PM
Huang JaneCMO, HematologyJun 08Sale170.84631107,8000Jun 10 05:13 PM
Wang XiaodongChair, Scientific Advisory BrdJun 08Sale170.916,0001,025,4550Jun 10 05:12 PM
Huang JaneCMO, HematologyMay 29Option Exercise29.491,50044,2351,500Jun 02 04:11 PM
Huang JaneCMO, HematologyMay 29Sale163.861,500245,7840Jun 02 04:11 PM
Glazer Donald W.DirectorMay 19Sale169.8410,0001,698,4000May 21 04:08 PM
OYLER JOHNChief Executive OfficerMay 01Sale141.434,635655,5370May 05 04:48 PM
Wu XiaobinPresident & GM ChinaMay 01Sale141.337,024992,7110May 05 04:46 PM
Huang JaneCMO, HematologyApr 29Option Exercise29.491,50044,2351,500Apr 30 04:04 PM
Huang JaneCMO, HematologyApr 29Sale162.301,500243,4500Apr 30 04:04 PM